Biotest Aktiengesellschaft (XETRA:BIO) — Market Cap & Net Worth
Market Cap & Net Worth: Biotest Aktiengesellschaft (BIO)
Biotest Aktiengesellschaft (XETRA:BIO) has a market capitalization of $976.15 Million (€834.96 Million) as of June 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #9172 globally and #1153 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotest Aktiengesellschaft's stock price €42.20 by its total outstanding shares 19785700 (19.79 Million). Review Biotest Aktiengesellschaft balance sheet liabilities to assess the company's total debt and financial obligations.
Biotest Aktiengesellschaft Market Cap History: 2015 to 2025
Biotest Aktiengesellschaft's market capitalization history from 2015 to 2025. Data shows growth from $430.49 Million to $976.15 Million (8.25% CAGR).
Biotest Aktiengesellschaft Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotest Aktiengesellschaft's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.31x
Biotest Aktiengesellschaft's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
36.10x
Biotest Aktiengesellschaft's market cap is 36.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $430.49 Million | $589.60 Million | -$82.50 Million | 0.73x | N/A |
| 2016 | $366.47 Million | $553.10 Million | -$45.80 Million | 0.66x | N/A |
| 2017 | $521.93 Million | $378.10 Million | -$3.50 Million | 1.38x | N/A |
| 2018 | $600.32 Million | $400.30 Million | $181.70 Million | 1.50x | 3.30x |
| 2019 | $443.31 Million | $419.10 Million | -$4.70 Million | 1.06x | N/A |
| 2020 | $666.19 Million | $484.20 Million | -$31.40 Million | 1.38x | N/A |
| 2021 | $987.72 Million | $515.60 Million | -$63.40 Million | 1.92x | N/A |
| 2022 | $990.03 Million | $516.10 Million | -$31.70 Million | 1.92x | N/A |
| 2023 | $985.40 Million | $684.60 Million | $127.00 Million | 1.44x | 7.76x |
| 2024 | $953.02 Million | $726.20 Million | $26.40 Million | 1.31x | 36.10x |
Competitor Companies of BIO by Market Capitalization
Companies near Biotest Aktiengesellschaft in the global market cap rankings as of June 19, 2026.
Key companies related to Biotest Aktiengesellschaft by market ranking:
- AcadeMedia AB (publ) (ST:ACAD): Ranked #9163 globally with a market cap of $979.06 Million USD ( Skr9.10 Billion SEK).
- ScanSource Inc (NASDAQ:SCSC): Ranked #9164 globally with a market cap of $978.63 Million USD.
- Shanghai Urban Architecture Design Co. Ltd. (SHE:300983): Ranked #9173 globally with a market cap of $976.04 Million USD ( CN¥6.67 Billion CNY).
- Brookline Bancorp Inc (NASDAQ:BRKL): Ranked #9174 globally with a market cap of $975.70 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #9163 | AcadeMedia AB (publ) | ST:ACAD | $979.06 Million | Skr94.90 |
| #9164 | ScanSource Inc | NASDAQ:SCSC | $978.63 Million | $49.63 |
| #9173 | Shanghai Urban Architecture Design Co. Ltd. | SHE:300983 | $976.04 Million | CN¥38.60 |
| #9174 | Brookline Bancorp Inc | NASDAQ:BRKL | $975.70 Million | $10.95 |
Biotest Aktiengesellschaft Historical Marketcap From 2015 to 2025
Between 2015 and today, Biotest Aktiengesellschaft's market cap moved from $430.49 Million to $ 976.15 Million, with a yearly change of 8.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €976.15 Million | +2.43% |
| 2024 | €953.02 Million | -3.29% |
| 2023 | €985.40 Million | -0.47% |
| 2022 | €990.03 Million | +0.23% |
| 2021 | €987.72 Million | +48.26% |
| 2020 | €666.19 Million | +50.28% |
| 2019 | €443.31 Million | -26.15% |
| 2018 | €600.32 Million | +15.02% |
| 2017 | €521.93 Million | +42.42% |
| 2016 | €366.47 Million | -14.87% |
| 2015 | €430.49 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 5th, 2026 the market cap of Biotest Aktiengesellschaft was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $976.15 Million USD |
| MoneyControl | $976.15 Million USD |
| MarketWatch | $976.15 Million USD |
| marketcap.company | $976.15 Million USD |
| Reuters | $976.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more